Wu-Chou Su
Wu-Chou Su, M.D.
Education
1976-1983: M.D.
College of Medicine, National Taiwan University, Taipei, Taiwan
Experience & Position
Aug 01, 1990-Sep 09, 2020:
Attending Physician, Division of Hematology/Oncology, Department of Internal Medicine,National Cheng Kung University Hospital, Tainan, Taiwan.
Jul 01, 2004-Jan 31, 2019:
Chief, Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Jan 01, 2006-Sep 30, 2011:
Director, Clinical Trial Center, National Cheng Kung University Hospital, Tainan, Taiwan.
Oct 01, 2011-Jul 31, 2017:
Director, Cancer Center, National Cheng Kung University Hospital, Tainan, Taiwan.
Aug 01, 2017-Jul 31, 2020:
Director, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Feb 01, 2019 -Jan 31, 2023:
Director, Department of Oncology, National Cheng Kung University Hospital, Tainan, Taiwan.
Oct 01, 2020 till now:
Attending Physician, Department of Oncology, National Cheng Kung University Hospital, Tainan, Taiwan.
Training
1982-1983: Rotating Internship
National Taiwan University Hospital, Taipei, Taiwan.
1983-1985: Military Service, Army Physician
1985-1987: Residency
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
1987-1990: Residency
(in the pay of National Cheng Kung University Hospital)
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
1988-1990: Fellowship
Medical Oncology Training Program
Institute of Biomedical Science, Academia Sinica, Taipei, Taiwan.
Aug 1995-May 1997:Research Fellow
Department of Pathology, Yale University School of Medicine, USA.
Academic Appointment:
1992-1997: Lecturer, Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Jul 01, 1997-Jul 30, 2004: Associate Professor, Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Aug 01, 2004-Jul 31, 2020: Professor, Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Jan 01, 2018 till now: Director, Center of Applied Nanomedicine, National Cheng Kung University, Tainan, Taiwan.
Aug 01, 2020 till now: Professor, Department of Oncology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Publications:
Refereed Papers ( * indicates Wu-Chou Su is the corresponding author of that paper)
1.Mengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, Jian Fang, D Ross Camidge, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Viola W Zhu, Michael Millward, Yun Fan, Wen-Tsung Huang, Ying Cheng, Liyan Jiang, Daniel Brungs, Lyudmila Bazhenova, Chee Khoon Lee, Bo Gao, Yan Xu, Wei-Hsun Hsu, Li Zheng, Pasi A Janne. Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations. Cancer Discovery (in press)
2. Szu-Chun Yang, Chien-Chung Lin, Yi-Lin Chen, Wu-Chou Su. Economic analysis of tissue-first, plasma-first, and complementary NGS approaches for treatment-naïve metastatic lung adenocarcinoma. Frontiers in Oncology 2022 May; 12: 873111.
3. Armando Santoro, Wu-Chou Su, Alejandro Navarro, Matteo Simonelli, James Ch Yang, Andrea Ardizzoni, Fabrice Barlesi, Jin Hyoung Kang, Sarah DiDominick, Ahmed Abdelhady, Xueying Chen, Uz Stammberger, Enriqueta Felip. Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer. Lung Cancer 2022 Apr; 166: 170-177.
4. Shun Lu, Qiming Wang, Guojun Zhang, Xiaorong Dong, Cheng-Ta Yang, Yong Song, Gee-Chen Chang, You Lu, Hongming Pan, Chao-Hua Chiu, Zhehai Wang, Jifeng Feng, Jianying Zhou, Xingxiang Xu, Renhua Guo, Jianhua Chen, Haihua Yang, Yuan Chen, Zhuang Yu, Her-Shyong Shiah, Chin-Chou Wang, Nong Yang, Jian Fang, Ping Wang, Kai Wang, Yanping Hu, Jianxing He, Ziping Wang, Jianhua Shi, Shaoshui Chen, Qiong Wu, Changan Sun, Chuan Li, Hongying Wei, Ying Cheng, Wu-Chou Su, Te-Chun Hsia, Jiuwei Cui, Yuping Sun, Sai-Hong Ignatius Ou, Viola W Zhu, James Chih-Hsin Yang. Efficacy of Aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: Updated post NMPA-approval results from the APOLLO registrational trial. Journal of Thoracic Oncology 2021 Mar; 17(3): 411-422.
5. Po-Lan Su, Jung-Yueh Chen, Chang-Yao Chu, Yi-Lin Chen, Wan-Li Chen, Kuan-Yu Lin, Chung-Liang Ho, Jeng-Shiuan Tsai, Szu-Chun Yang, Chian-Wei Chen, Yi-Lin Wu, Yau-Lin Tseng, Chao-Chun Chang, Yi-Ting Yen, Chia-Ying Lin, Chien-Chung Lin*, Wu-Chou Su. The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy. Scientific Reports 2022 Feb; 12(1): 3319.
6. Paolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, Todd M Bauer, Marcello Tucci, Antoine Italiano, Roberto Iacovelli, Wu-Chou Su, Christophe Massard, Mansoor Saleh, Gennaro Daniele, Alastair Greystoke, Martin Gutierrez, Shubham Pant, Ying-Chun Shen, Matteo Perrino, Robin Meng, Giovanni Abbadessa, Helen Lee, Yingwen Dong, Marielle Chiron, Rui Wang, Laure Loumagne, Lucie Lépine, Johann de Bono. Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. Journal for ImmunoTherapy of Cancer 2022 Jan; 10(1): e003697.
7. Hai-Yan Tu, Jifeng Feng, Meiqi Shi, Jun Zhao, Yuyan Wang, Jianhua Chang, Jialei Wang, Ying Cheng, Jing Zhu, Eng-Huat Tan, Kai Li, Yiping Zhang, Victor Lee, Cheng-Ta Yang, Wu-Chou Su, David Chi-Leung Lam, B J Srinivasa, Senthil Rajappa, Ching-Liang Ho, Kwok Chi Lam, Yi Hu, Shailesh Arjun Bondarde, Xiaoqing Liu, Yahui Tian, Zhiyi Xue, Agnieszka Cseh, Dennis Chin-Lun Huang, Caicun Zhou, Yi-Long Wu. A phase IIIb open-label, single-arm study of Afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC: final analysis, with a focus on patients enrolled at sites in China. Targeted Oncology 2022 Jan; 17(1): 1-13.
8. Pei-Shan Yang, Min-Hua Yu, Ya-Chin Hou, Chih-Peng Chang, Shao-Chieh Lin, I-Ying Kuo, Pei-Chia Su, Hung-Chi Cheng, Wu-Chou Su, Yan-Shen Shan, Yi-Ching Wang. Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy. Theranostics 2022 Jan; 12(1): 340-361.
9. Wei-Pang Chung, Wei-Lun Huang, Wei-An Liao, Chun-Hua Hung, Chi-Wu Chiang, Chun Hei Antonio Cheung*, Wu-Chou Su*. FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer. Scientific Reports 2022 Jan, 12(1): 241.
10.Sheng-Yuan Wang, Ching-Han Lai, Chian-Wei Chen, Szu-Chun Yang, Chao-Chun Chang, Chia-Ying Lin, Yi-Ting Yen, Yau-Lin Tseng, Po-Lan Su*, Chien-Chung Lin*, Wu-Chou Su. Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors. Thoracic Cancer 2022 Jan; 13(2): 182-189.
11.Pasi A Janne, Christina Baik, Wu-Chou Su, Melissa L Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A Gold, Conor E Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A Yu. Efficacy and safety of Patritumab Deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discovery 2022 Jan; 12(1): 74-89.
12.Antoine Hollebecque, Hyun C Chung, Maria J de Miguel, Antoine Italiano, Jean-Pascal Machiels, Chai-Chi Lin, Neesha C Dhani, Marc Peeters, Victor Moreno, Wu-Chou Su, Kay Hoong Chow, Violeta R Galvao, Michelle Carlsen, Danni Yu, Anna M Szpurka, Yumin Zhao, Shelly L Schmidt, Leena Gandhi, Xiaojian Xu, Yung-Jue Bang. Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors. Clinical Cancer Research 2021 Dec; 27(23): 6393-6404.
13.Szu-Chun Yang, Natalia Kunst, Cary P Gross, Jung-Der Wang, Wu-Chou Su, Shi-Yi Wang. Cost-effectiveness of Nivolumab plus Ipilimumab with and without chemotherapy for advanced non-small cell lung cancer. Frontiers in Oncology 2021 Dec; 11: 760686.
14.Yi-Hsuan Huang, Peng-Chan Lin, Wu-Chou Su, Ren-Hao Chan, Po-Chuan Chen, Bo-Wen Lin, Meng-Ru Shen, Shang-Hung Chen, Yu-Min Yeh. Association between altered oncogenic signaling pathways and overall survival of patients with metastatic colorectal cancer. Diagnostics 2021 Dec; 11(12): 2308.
15.Yu-Min Yeh, Peng-Chan Lin, Wu-Chou Su, Meng-Ru Shen. CD40 pathway and IL-2 expression mediate the differential outcome of colorectal cancer patients with different CSF1R c.1085 genotypes. International Journal of Molecular Sciences 2021 Nov; 22(22): 12565.
16.Yen-Ting Lin, Chi-Lu Chiang, Jen-Yu Hung, Mei-Hsuan Lee, Wu-Chou Su, Shang-Yin Wu, Yu-Feng Wei, Kang-Yun Lee, Yen-Han Tseng, Jian Su, Hsin-Pei Chung, Chih-Bin Lin, Wen-Hui Ku, Tsai-Shin Chiang, Chao-Hua Chiu, Jin-Yuan Shih. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. European Journal of Cancer 2021 Oct; 156: 1-11.
17.Roy S Herbst, Edward B Garon, Dong-Wan Kim, Byoung Chul Cho, Radj Gervais, Jose L Perez-Gracia, Ji-Youn Han, Margarita Majem, Martin D Forster, Isabelle Monnet, Silvia Novello, Matthew A Gubens, Michael Boyer, Wu-Chou Su, Ayman Samkari, Erin H Jensen, Julie Kobie, Bilal Piperdi, Paul Baas. 5-year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death ligand 1-positive advanced non-small-cell lung cancer. Journal of Thoracic Oncology 2021 Oct; 16(10): 1718-1732.
18.Sheng-Kai Liang, Li-Hsin Chien, Gee-Chen Chang, Ying-Huang Tsai, Wu-Chou Su, Yuh-Min Chen, Ming-Shyan Huang, Hsien-Chih Lin, Wen-Tsen Fang, Hsiao-Han Hung, Shih-Sheng Jiang, Chih-Yi Chen, Kuan-Yu Chen, I-Shou Chang, Chao A Hsiung, Chien-Jen Chen, Pan-Chyr Yang, GELAC Study Group. Programmed death ligand 2 gene polymorphisms are associated with lung adenocarcinoma risk in female never-smokers. Frontiers in Oncology 2021 Sep; 11: 753788.
19.Keunchil Park, Daniel Shao Weng Tan, Wu-Chou Su, Byoung Chul Cho, Sang-We Kim, Ki Hyeong Lee, Chin-Chou Wang, Takashi Seto, Dennis Chin-Lun Huang, Helen Hayoun Jung, Ming-Chi Hsu, Thomas Bogenrieder, Chia-Chi Lin. Phase 1b open-label trial of Afatinib plus Xentuzumab (BI 836845) in patients with EGFR mutation-positive NSCLC after progression on EGFR tyrosine kinase inhibitors. JTO Clinical and Research Reports 2021 Sep; 2(9): 100206.
20.Yi-Lin Chen, Wan-Li Chen, Yi-Chia Cheng, Ming-Ching Lin, Shu-Ching Yang, Hung-Wen Tsai, Chien-Chung Lin, Wu-Chou Su, Nan-Haw Chow, Chung-Liang Ho. Development of a novel ALK rearrangement screening test for non-small cell lung cancers. PLoS One 2021 Sep; 16(9): e0257152.
21.Jeng-Shiuan Tsai, Po-Lan Su, Szu-Chun Yang, Chao-Chun Chang, Chia-Ying Lin, Yi-Ting Yen, Yau-Lin Tseng, Wu-Wei Lai, Chien-Chung Lin*, Wu-Chou Su. EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis. Journal of the Formosan Medical Association 2021 Sep; 120(9): 1729-1739.
22.Po-Lan Su, Chien-Yu Lin, Yi-Lin Chen, Wan-Li Chen, Chien-Chung Lin, Wu-Chou Su*. Durable response to combined Dabrafenib and Trametinib in a patient with BRAF K601E mutation-positive lung adenocarcinoma: A case report. JTO Clinical and Research Reports 2021 Aug; 2(8): 100202
23.Po-Lan Su, Jeng-Shiuan Tsai, Szu-Chun Yang, Yi-Lin Wu, Yau-Lin Tseng, Chao-Chun Chang, Yi-Ting Yen, Chia-Ying Lin, Chien-Chung Lin*, Chin-Chou Wang*, Meng-Chih Lin, Wu-Chou Su. Survival benefit of Osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to Osimertinib treatment. Lung Cancer 2021 Aug; 158: 137-145.
24.Pasi A Janne, Christina Baik, Wu-Chou Su, Melissa L Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A Gold, Conor E Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A Yu. Efficacy and safety of Patritumab Deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discovery (2021 inpress)
25.Antoine Hollebecque, Hyun C Chung, Maria J de Miguel, Antoine Italiano, Jean-Pascal Machiels, Chai-Chi Lin, Neesha C Dhani, Marc Peeters, Victor Moreno, Wu-Chou Su, Kay Hoong Chow, Violeta R Galvao, Michelle Carlsen, Danni Yu, Anna M Szpurka, Yumin Zhao, Shelly L Schmidt, Leena Gandhi, Xiaojian Xu, Yung-Jue Bang. Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors. Clinical Cancer Research (2021 inpress)
26.Yen-Ting Lin, Chi-Lu Chiang, Jen-Yu Hung, Mei-Hsuan Lee, Wu-Chou Su, Shang-Yin Wu, Yu-Feng Wei, Kang-Yun Lee, Yen-Han Tseng, Jian Su, Hsin-Pei Chung, Chih-Bin Lin, Wen-Hui Ku, Tsai-Shin Chiang, Chao-Hua Chiu, Jin-Yuan Shih. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. European Journal of Cancer 2021 Oct; 156: 1-11.
27.Roy S Herbst, Edward B Garon, Dong-Wan Kim, Byoung Chul Cho, Radj Gervais, Jose L Perez-Gracia, Ji-Youn Han, Margarita Majem, Martin D Forster, Isabelle Monnet, Silvia Novello, Matthew A Gubens, Michael Boyer, Wu-Chou Su, Ayman Samkari, Erin H Jensen, Julie Kobie, Bilal Piperdi, Paul Baas. 5-year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death ligand 1-positive advanced non-small-cell lung cancer. Journal of Thoracic Oncology 2021 Oct; 16(10): 1718-1732.
28.Yi-Lin Chen, Wan-Li Chen, Yi-Chia Cheng, Ming-Ching Lin, Shu-Ching Yang, Hung-Wen Tsai, Chien-Chung Lin, Wu-Chou Su, Nan-Haw Chow, Chung-Liang Ho. Development of a novel ALK rearrangement screening test for non-small cell lung cancers. PLoS One 2021 Sep; 16(9): e0257152.
29.Jeng-Shiuan Tsai, Po-Lan Su, Szu-Chun Yang, Chao-Chun Chang, Chia-Ying Lin, Yi-Ting Yen, Yau-Lin Tseng, Wu-Wei Lai, Chien-Chung Lin*, Wu-Chou Su. EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis. Journal of the Formosan Medical Association 2021 Sep; 120(9): 1729-1739.
30.Po-Lan Su, Jeng-Shiuan Tsai, Szu-Chun Yang, Yi-Lin Wu, Yau-Lin Tseng, Chao-Chun Chang, Yi-Ting Yen, Chia-Ying Lin, Chien-Chung Lin*, Chin-Chou Wang*, Meng-Chih Lin, Wu-Chou Su. Survival benefit of Osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to Osimertinib treatment. Lung Cancer 2021 Aug; 158: 137-145.
31.Yen-Hsiang Huang, Jen-Yu Hung, How-Wen Ko, Po-Lan Su, Chun-Liang Lai, Huang-Chih Chang, Te-Chun Hsia, Sheng-Hao Lin, Kuan-Li Wu, Cheng-Ta Yang, Wu-Chou Su, Yi-Chun Chu, Chin-Chou Wang, Wei-Yu Liao, Yen-Ting Lin, Ching-Hsiung Lin, Meng-Chih Lin, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Mei-Hsuan Lee, Sung-Liang Yu, Chao-Chi Ho, Gee-Chen Chang. The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. Therapeutic Advances in Medical Oncology 2021 May; 13: 1-12.
32.I-Ying Kuo, You-En Yang, Pei-Shan Yang, Yu-Jou Tsai, Hong-Tai Tzeng, Hung-Chi Cheng, Wan-Ting Kuo, Wu-Chou Su, Chih-Peng Chang, Yi-Ching Wang. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. Theranostics 2021 May; 11(14): 7029-7044.
33.Chun-Yan Shih, Wei-Lun Huang, I-Ting Chiang, Wu-Chou Su*, Hsisheng Teng*. Biocompatible hole scavenger-assisted graphene oxide dots for photodynamic cancer therapy. Nanoscale 2021 May; 13(8): 8431-8441.
34.Her-Shyong Shiah, Nai-Jung Chiang, Chia-Chi Lin, Chia-Jui Yen, Hui-Jen Tsai, Shang-Yin Wu, Wu-Chou Su, Kwang-Yu Chang, Ching-Chiung Wang, Jang-Yang Chang, Li-Tzong Chen. Phase I dose-escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors. Oncologist 2021 Apr; 26(4): e567-e579.
35.Wei-Pang Chung, Wei-Lun Huang, Wei-An Liao, Wan-Ling Huang, You-Yu Liu, Wu-Chou Su*. Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models. Cancer Medicine 2021 Mar; 10(7): 2370-2379.
36.Tsung-Lin Tsai, Yu-Hsuan Lai, Helen HW Chen, Wu-Chou Su*. Overcoming radiation resistance by iron-platinum metal alloy nanoparticles in human copper transport 1-overexpressing cancer cells via mitochondrial disturbance. International Journal of Nanomedicine 2021Mar; 2021(16): 2071-2085.
37.Hui-Jen Tsai, Her-Shyong Shiah, Jang-Yang Chang, Wu-Chou Su, Nai-Jung Chiang, Li-Tzong Chen. Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors. Scientific Reports 2021 Mar; 11(1): 4834.
38.Amita Patnaik, Timothy A Yap, Hyun Cheol Chung, Maria de Miguel, Yung-Jue Bang, Chia-Chi Lin, Wu-Chou Su, Antoine Italiano, Kay Hoong Chow, Anna M Szpurka, Danni Yu, Yumin Zhao, Michelle Carlsen, Shelly Schmidt, Burkhard Vangerow, Leena Gandhi, Xiaojian Xu, Johanna C Bendell. Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial. Clinical Cancer Research 2021 Mar; 27(5): 1267-1277.
39.Po-Lan Su, Chian-Wei Chen, Yi-Lin Wu, Chien-Chung Lin, Wu-Chou Su. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer. Thoracic Cancer 2021 Feb; 12(3): 287-296.
40.Chun-Yan Shih, Pei-Ting Wang, Wu-Chou Su, Hsisheng Teng, Wei-Lun Huang. Nanomedicine-based strategies assisting photodynamic therapy for hypoxic tumors: state-of-the-art approaches and emerging trends. Biomedicines 2021 Feb, 9(2): 137.
41.Chien-Chung Lin, Chin-You Wu, Joseph T Tseng, Chun-Hua Hung, Shang-Yin Wu, Yu-Ting Huang, Wei-Yuan Chang, Po-Lan Su, Wu-Chou Su*. Extracellular vesicle miR-200c enhances Gefitinib sensitivity in Heterogeneous EGFR-mutant NSCLC. Biomedicines 2021 Feb; 9(3): 243.
42.Batel Blechter, Jason Y Y Wong, Chao Agnes Hsiung, H Dean Hosgood, Wu-Chou Su, Qing Lan et al. Sub-multiplicative interaction between polygenic risk score and household coal use in relation to lung adenocarcinoma among never-smoking women in Asia. Environment International 2021 Feb; 147: 105975.
43.James Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, Jianying Zhou, Renhua Guo, Chao-Hua Chiu, Gee-Chen Chang, Her-Shyong Shiah, Yuan Chen, Chin-Chou Wang, David Berz, Wu-Chou Su, Nong Yang, Ziping Wang, Jian Fang, Jianhua Chen, Petros Nikolinakos, You Lu, Hongming Pan, Ajit Maniam, Lyudmila Bazhenova, Keisuke Shirai, Mohammad Jahanzeb, Maurice Willis, Nehal Masood, Naveed Chowhan, Te-Chun Hsia, Hong Jian, Shun Lu. Safety, Efficacy and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients with EGFR-mutated Advanced NSCLC: a Multicenter, Open-label, Phase I Trial. Journal of Thoracic Oncology 2020 Dec; 15(12): 1907-1918.
44.Her-Shyong Shiah, Nai-Jung Chiang, Chia-Chi Lin, Chia-Jui Yen, Hui-Jen Tsai, Shang-Yin Wu, Wu-Chou Su, Kwang-Yu Chang, Ching-Chiung Wang, Jang-Yang Chang, Li-Tzong Chen. Phase I dose-escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors. Oncologist 2020 Dec; 25: 1-13.
45.Yuh-Min Chen, James Chih-Hsin Yang, Wu-Chou Su, Inn-Wen Chong, Te-Chun Hsia, Meng-Chih Lin, Gee-Chen Chang, Chao-Hua Chiu, Chao-Chi Ho, Shang-Yin Wu, Jen-Yu Hung, Chin-Chou Wang, Tsung-Ying Yang, Chong-Jen Yu. Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan. Journal of the Formosan Medical Association 2020 Dec; 119(2): 1817-1826.
46.V.A. Papadimitrakopoulou, T.S. Mok, J.-Y. Han, M.J. Ahn, A. Delmonte, S.S. Ramalingam, S.W. Kim, F.A. Shepherd, J. Laskin, Y. He, H. Akamatsu, W.S.M.E. Theelen, Wu-Chou Su, T. John, M. Sebastian, H. Mann, M. Miranda, G. Laus, Y. Rukazenkov, Y.-L. Wu. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Annals of Oncology 2020 Nov; 31(11): 1536-1544.
47.Chien-Yao Sun, Chien-Cheng Huang, Yuh-Shyan Tsai, Yu-Tzu Chang, Chien-Hui Ou, Wu-Chou Su, Sheng-Yu Fan, Shan-Tair Wang, Deng-Chi Yang, Chi-Chang Huang, Chia-Ming Chang. Clinical frailty scale in predicting postoperative outcomes in older patients undergoing curative surgery for urologic malignancies: a prospective observational cohort study. Urology 2020 Oct; 144: 38-45.
48.Michael Tu, Jordan Cheng, Yi-Lin Chen, Wen-Chien Jea, Wan-Li Chen, Chien-Jung Chen, Chung-Liang Ho, Wei-Lun Huang, Chien-Chung Lin, Wu-Chou Su, Qianlin Ye, Josh Deignan, Wayne Grody, Feng Li, David Chia, Fang Wei, Wei Liao, David T.W. Wong, Charles M Strom. Electric Field Induced Release and Measurement (EFIRM): Characterization and technical validation of a novel liquid biopsy platform in plasma and saliva. Journal of Molecular Diagnostics 2020 Aug; 22(8): 1050-1062.
49.Yi-Te Huang, Ya-Ping Chen, Wen-Chih Lin, Wu-Chou Su, Yuan-Ting Sun. Immune checkpoint inhibitor-induced myasthenia gravis. Frontiers in Neurology 2020 Jul; 11: 634.
50.Hsin-Yi Wu, Yu-Yi Pan, Arthur T. Kopylov, Victor Zgoda, Mi-Chia Ma, Ching-Hsun Wang, Wu-Chou Su, Wu-Wei Lai, Pin-Nan Cheng, Pao-Chi Liao. Assessment of serological early biomarker candidates for lung adenocarcinoma by using multiple reaction monitoring-mass spectrometry. Proteomics Clinical Application 2020 Jul; 14(4): 1900095.
51.Feng Li*, Fang Wei, Wei-Lun Huang, Chien-Chung Lin, Liang Li, Macy M. Shen, Qingxiang Yan, Wei Liao, David Chia, Michael Tu, Jason H. Tang, Ziding Feng, Yong Kim, Wu-Chou Su*, David T.W. Wong*. Ultra-short circulating tumor DNA (usctDNA) in plasma and saliva of non-small cell lung cancer (NSCLC) patients. Cancers 2020 Jul; 12(8): 2041.
52.Li-Xing Yang, Ya-Na Wu, Pei-Wen Wang, Kuang-Jing Huang, Wu-Chou Su*, Dar-Bin Shieh*. Silver-coated zero-valent iron nanoparticles enhance cancer therapy in mice through lysosome-dependent dual programed cell death pathways: triggering simultaneous apoptosis and autophagy only in cancerous cells. Journal of Materials Chemistry B 2020 May; 8(18): 4122-4131.
53.Roy S. Herbst, Edward B. Garon, Dong-Wan Kim, Byoung Chul Cho, Jose L. Perez-Gracia, Ji-Youn Han, Catherine Dubos Arvis, Margarita Majem, Martin D. Forster, Isabelle Monnet, Silvia Novello, Zsuzsanna Szalai, Matthew A. Gubens, Wu-Chou Su, Giovanni Luca Ceresoli, Ayman Samkari, Erin H. Jensen, Gregory M. Lubiniecki, Paul Baas. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 Study. Journal of Clinical Oncology 2020 May; 38(14): 1580-1590.
54.Szu-Chun Yang, Wu-Wei Lai, Jason C. Hsu, Wu-Chou Su, Jung-Der Wang. Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan. PLoS One 2020 Apr; 15(4): e0231413.
55.Tzu-Yu Chen, Yao-Hwei Fang, Hui-Ling Chen, Chin-Hao Chang, Hsin Huang, Yi-Song Chen, Kuo-Meng Liao, Hsiao-Yu Wu, Gee-Chen Chang, Ying-Huang Tsai, Chih-Liang Wang, Yuh-Min Chen, Ming-Shyan Huang, Wu-Chou Su, Pan-Chyr Yang, Chien-Jen Chen, Chin-Fu Hsiao, Chao A. Hsiung. Impact of cooking oil fume exposure and fume extractor use on lung cancer risk in non-smoking Han Chinese women. Scientific Reports 2020 Apr; 10(1): 6774.
56.Makoto Nishio, Enriqueta Felip, Sergey Orlov, Keunchil Park, Chong-Jen Yu, Chun-Ming Tsai, Manuel Cobo, Mark McKeage, Wu-Chou Su, Tony Mok, Giorgio V. Scagliotti, David R. Spigel, Kalyanee Viraswami-Appanna, Zhe Chen, Vanessa Q. Passos, Alice T. Shaw. Final overall survival and other efficacy and safety results from ASCEND-3: phase II study of Ceritinib in ALKi-naive patients with ALK-rearranged NSCLC. Journal of Thoracic Oncology 2020 Apr; 15(4): 609-617.
57.Lecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Sang-We Kim, James Chih-Hsin Yang, Jong Seok Lee, Wu-Chou Su, Dariusz Kowalski, Sergey Orlov, Mireille Cantarini, Remy B Verheijen, Anders Mellemgaard, Lone Ottesen, Paul Frewer, Xiaoling Ou, Geoffrey Oxnard. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. The Lancet Oncology 2020 Mar; 21(3): 373-386.
58.Jason Y.Y. Wong, Han Zhang, Chao A. Hsiung, Kouya Shiraishi, Wu-Chou Su, Qing Lan et al. Tuberculosis infection and lung adenocarcinoma: mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women. Genomics 2020 Mar; 112(2): 1223-1232.
59.Yung‐Jue Bang, Wu‐Chou Su, Martin Schuler, Do‐Hyun Nam, Wan Teck Lim, Todd M. Bauer, Analia Azaro, Ronnie Tung Ping Poon, David Hong, Chia‐Chi Lin, Mikhail Akimov, Samson Ghebremariam, Sylvia Zhao, Monica Giovannini, Brigette Ma. Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts. Cancer Science 2020 Feb; 111(2): 536-547.
60.Li-Hsin Chien, Chung-Hsing Chen, Tzu-Yu Chen, Gee-Chen Chang, Ying-Huang Tsai, Chin-Fu Hsiao, Kuan-Yu Chen, Wu-Chou Su, Wen-Chang Wang, Ming-Shyan Huang, Yuh-Min Chen, Chih-Yi Chen, Sheng-Kai Liang, Chung-Yu Chen, Chih-Liang Wang, Mei-Hsuan Lee, Ren-Hua Chung, Fang-Yu Tsai, Jia-Wei Hu, Hormuzd A. Katki, Nilanjan Chatterjee, Stephen J. Chanock, Nathaniel Rothman, Qing Lan, Pan-Chyr Yang, Chien-Jen Chen, I-Shou Chang, Chao A. Hsiung. Predicting lung cancer occurrence in never-smoking females in Asia: TNSF-SQ, a prediction model. Cancer Epidemiology Biomarkers & Prevention 2020 Feb 29(2): 452-459.
61.Szu-Chun Yang, Chin-Wei Kuo, Wu-Wei Lai, Chien-Chung Lin, Wu-Chou Su, Sheng-Mao Chang, Jung-Der Wang. Dynamic changes of health utility in lung cancer patients receiving different treatments: a 7-year follow-up. Journal of Thoracic Oncology 2019 Nov; 14(11): 1892-1900.
62.Jhanelle E. Gray, Isamu Okamoto, Virote Sriuranpong, Johan F. Vansteenkiste, Fumio Imamura, Jong-Seok Lee, Yong-Kek Pang, Manuel Cobo, Kazuo Kasahara, Ying Cheng, Naoyuki Nogami, Eun Kyung Cho, Wu-Chou Su, Guili Zhang, Xiangning Huang, Xiaocheng Li-Sucholeiki, Brian Lentrichia, Simon P. Dearden, Suzanne Jenkins, Matilde Saggese, Yuri Rukazenkov, Suresh Ramalingam. Tissue and plasma EGFR mutation analysis in the FLAURA trial: Osimertinib vs comparator EGFR-TKI as first-line treatment in patients with EGFR mutated advanced NSCLC. Clinical Cancer Research 2019 Nov; 25(22): 6644-6652.
63.Po-Lan Su, Szu-Chun Yang, Yi-Lin Chen, Yi-Lin Wu, Chia-Ying Lin, Wei-Yuan Chang, Yau-Lin Tseng, Wu-Wei Lai, Chung-Liang Ho*, Chien-Chung Lin*, Wu-Chou Su*. Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatment. Cancer Medicine 2019 Oct; 8(13): 5939-5947.
64.Li-Xing Yang, Ya-Na Wu, Pei-Wen Wang, Wu-Chou Su*, Dar-Bin Shieh*. Iron release profile of Silica-modified zero-valent iron NPs and their implication in cancer therapy. International Journal of Molecular Sciences 2019 Sep; 20(18): 4336.
65.Chia-Ying Lin, Chao-Chun Chang, Po-Lan Su, Chien-Chung Lin, Yau-Lin Tseng, Wu-Chou Su, Yi-Ting Yen. Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC. Medicine 2019 Aug; 98(33): e16766.
66.Yi-Lin Chen, Chien-Chung Lin, Shu-Ching Yang, Wan-Li Chen, Jian-Rong Chen, Yi-Hsin Hou, Cheng-Chan Lu, Nan-Haw Chow, Wu-Chou Su, Chung-Liang Ho. Five technologies for detecting the EGFR T790M mutation in the circulating cell-free DNA of patients with non-small cell lung cancer: a comparison. Frontiers in Oncology 2019 Jul; 9: 631.
67.Chia-Chi Lin, Hendrik-Tobias Arkenau, Sharon Lu, Jasgit Sachdev, Javier de Castro Carpeno, Monica Mita, Rafal Dziadziuszko, Wu-Chou Su, Dmitri Bobilev, Lorraine Hughes, Jian Chan, Zhi-Yi Zhang, Glen J. Weiss. A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. British Journal of Cancer 2019 Jul; 121(2): 131-138.
68.James Chih-Hsin Yang, Shirish M. Gadgeel, Lecia Van Dam Sequist, Chien-Liang Wu, Vassiliki A. Papadimitrakopoulou, Wu-Chou Su, Joseph Fiore, Sanatan Saraf, Harry Raftopoulos, Amita Patnaikh. Brief report: Pembrolizumab in combination with Erlotinib or Gefitinib as first-line therapy for advanced non-small-cell lung cancer with sensitizing EGFR mutation. Journal of Thoracic Oncology 2019 Mar; 14(3): 553-559.
69.Helen H. W. Chen, Wu-Chou Su, How-Ran Guo, Bi-Fang Lee, Nan-Tsing Chiu. Prognostic value of volumetric metabolic parameter changes determined by during and after radiotherapy-based 18F-FDG PET/CT in stage III non-small cell lung cancer. Kaohsiung Journal of Medical Sciences 2019 Mar; 35(3): 151-159.
70.Chung-Ying Lin, Jing-Shiang Hwang, Wen-Chung Wang, Wu-Wei Lai, Wu-Chou Su, Tzu-Yi Wu, Grace Yao, Jung-Der Wang. Psychometric evaluation of the WHOQOL-BREF, Taiwan version, across five kinds of Taiwanese cancer survivors: Rasch analysis and confirmatory factor analysis. Journal of the Formosan Medical Association 2019 Jan; 118(1): 215-222.
71.Thomas John, Hiroaki Akamatsu, Angelo Delmonte, Wu-Chou Su, Jong Seok Lee, Gee-Chen Chang, Xiangning Huang, Suzanne Jenkins, Yi-Long Wu. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. Lung Cancer 2018 Dec; 126: 133-138.
72.Yu-Feng Wei, Chang-Yao Chu, Chao-Chun Chang, Sheng-Hsiang Lin, Wu-Chou Su, Yau-Lin Tseng, Chien-Chung Lin, Yi-Ting Yen. Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma. Lung Cancer 2018 Nov; 125: 35-42.
73.Fang Wei, Charles M. Strom, Jordan Cheng, Chien-Chung Lin, Ching-Yun Hsu, Guy W. Soo Hoo, David Chia, Yong Kim, Feng Li, David Elashoff, Tristan Grognan, Michael Tu, Wei Liao, Rena Xian, Wayne W. Grody, Wu-Chou Su*, David T.W. Wong*. Electric field-induced release and measurement liquid biopsy for noninvasive early lung cancer assessment. Journal of Molecular Diagnostics 2018 Nov; 20(6): 738-742.
74.Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F. Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S.W. Tan. Phase Ib/II Study of Capmatinib (INC280) plus Gefitinib after failure of Epidermal Growth Factor Receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. Journal of Clinical Oncology 2018 Nov; 36(31): 3101-3109.
75.Hong-Tai Tzeng, Ching-Chin Su, Chih-Peng Chang, Wu-Wei Lai, Wu-Chou Su, Yi-Ching Wang. Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages towards tumor-suppressing phenotype. International Journal of Cancer 2018 Oct; 143(7): 1753-1763.
76.Po-Lan Su, Yi-Lin Wu, Wei-Yuan Chang, Chung-Liang Ho, Yau-Lin Tseng, Wu-Wei Lai, Wu-Chou Su, Chien-Chung Lin, Szu-Chun Yang. Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology 2018 Sep; 10: 1758835918797589.
77.Yan-Wei Wu, Chiou-Feng Lin, Yee-Shin Lin, Wu-Chou Su, Wei-Hsin Chiu. Autophagy regulates vinorelbine sensitivity due to continued Keap1-mediated ROS generation in lung adenocarcinoma cells. Cell Death Discovery 2018 Sep; 4: 96.
78.Shu-Huei Cho, I-Ying Kuo, Pei-Jung Frank Lu, Hong-Tai Tzeng, Wu-Wei Lai, Wu-Chou Su, Yi-Ching Wang. Rab37 mediates exocytosis of secreted frizzled-related protein 1 to inhibit Wnt signaling and thus suppress lung cancer stemness. Cell Death & Disease 2018 Aug; 9(9): 868.
79.David E Gerber, Leora Horn, Michael Boyer, Rachel Sanborn, Ronald Natale, Ramon Palmero, Paolo Bidoli, Igor Bondarenko, Paul Germonpre, Doru Ghizdavescu, Athanasio Kotsaki, Herve Lena, György Losonczy, Kyunghee Park, Wu-Chou Su, Min Tang, Jennifer Lai, Niko Letta Kallinteris, Joseph S Shan, Martin Reck, David R Spigel. Randomized phase 3 study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. Annals of Oncology 2018 July; 29(7): 1548-1553.
80.Chih-Chieh Yen, Hui-Chen Su, Chang-Yao Chu, Shi-Jie Lai, Jing-Jou Yana, Wen-Pin Su*, Wu-chou Su*. Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy. Lung Cancer 2018 Jun; 120: 149-151.
81.Szu-Chun Yang, Chien-Chung Lin, Wu-Wei Lai, Sheng-Mao Chang, Jing-Shiang Hwang, Wu-Chou Su, Jung-Der Wang. Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer. Therapeutic Advances in Medical Oncology 2018 Feb; 10: 1-11.
82.Wei-Yuan Chang, Yi-Lin Wu, Po-Lan Su, Szu-Chun Yang*, Chien-Chung Lin*, Wu-Chou Su*. The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. PLoS One 2018 Feb; 13(2): e0192161.
83.Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Byoung Chul Cho, Ying Cheng, Eun Kyung Cho, osimPei Jye Voon, David Planchard, Wu-Chou Su, Jhanelle E. Gray, Siow-Ming Lee, Rachel Hodge, Marcelo Marotti, Yuri Rukazenkov, Suresh S. Ramalingam, for the FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. New England Journal of Medicine 2018 Jan; 378(2): 113-125.
84.Myung-Ju Ahn, Dong-Wan Kim, Byoung Chul Cho, Sang-We Kim, Jong Seok Lee, Jin-Seok Ahn, Tae Min Kim, Chia-Chi Lin, Hye Ryun Kim, Thomas John, Steven Kao, Jonathan W Goldman, Wu-Chou Su, Ronald Natale, Sarit Rabbie, Bryony Harrop, Philip Overend, Zhenfan Yang, James Chih-Hsin Yang. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. The Lancet Respiratory Medicine 2017 Nov; 5(11): 891-902.
85.Kundan Sivashanmugana#, Wei-Lun Huang#, Chen-Hsueh Lin, Jiunn-Der Liao, Chien-Chung Lin, Wu-Chou Su*, Ten-China Wen*. Bimetallic nanoplasmonic gap-mode SERS substrate for lung normal and cancer-derived exosomes detection. Journal of the Taiwan Institute of Chemical Engineers 2017 Nov; 80, 149-155.
86.Tsung-Lin Tsai, Hao-Chen Wang, Chun-Hua Hung, Peng-Chan Lin, Yi-San Lee, Helen H. W. Chen*, Wu-Chou Su*. Wheat germ agglutinin-induced paraptosis-like cell death and protective autophagy is mediated by autophagy-linked FYVE inhibition. Oncotarget 2017 Oct; 8(53): 91209-91222.
87.Kenneth S. Thress, Vivien Jacobs, Helen K. Angell, James Chih-Hsin Yang, Lecia V. Sequist, Fiona Blackhall, Wu-Chou Su, Martin Schuler, Jurgen Wolf, Kathryn A. Gold, Mireille Cantarini, J. Carl Barrett, Pasi A. Jänne. Modulation of biomarker expression by osimertinib: Results of the paired tumor biopsy cohorts of the AURA Phase I trial. Journal of Thoracic Oncology 2017 Oct; 12(10): 1588-1594.
88.Yu-Min Yeh, Shan-Ju Hsu, Peng-Chan Lin, Keng-Fu Hsu, Pei-Ying Wu, Wu-Chou Su, Jang-Yang Chang, Meng-Ru Shen. The c.1085A>G genetic variant of CSF1R gene regulates tumor immunity by altering the proliferation, polarization, and function of macrophages. Clinical Cancer Research 2017 Oct; 23(20): 6021-6030.
89.Wen-Pin Su, Yen-Chih Ho, Cheng-Kuei Wu, Sen-Huei Hsu, Jia-Lin Shiu, Jheng-Cheng Huang, Song-Bin Chang, Wen-Tai Chiu, Jan-Jong Hung, Tsung-Lin Liu, Wei-Sheng Wu, Pei-Yu Wu, Wu-Chou Su, Jang-Yang Chang, Hungjiun Liaw. Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways. Scientific Reports 2017 Jun; 7: 3879.
90.Szu-Chun Yang, Wu-Wei Lai, Chien-Chung Lin, Wu-Chou Su, Li-Jung Ku, Jing-Shiang Hwang, Jung-Der Wang. Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan. Lung Cancer 2017 Jun; 108: 183-191.
91.Chien-Wei Chen, Chin-Wei Kuo, Yi-Lin Chen, Chung-Liang Ho, Wu-Chou Su, Chien-Chung Lin. Successful AZD9291 therapy in advanced non-small cell lung cancer after failure of HM61713. Journal of Thoracic Oncology 2017 Jun; 12(6): e72-e74.
92.Shao-An Wang, Yi-Chang Wang, Yun-Pei Chuang, Yi-Han Huang, Wu-Chou Su, Wen-Chang Chang, Jan-Jong Hung. EGF-mediated inhibition of ubiquitin-specific peptidase 24 expression has a crucial role in tumorigenesis. Oncogene 2017 May; 36(21): 2930-2945.
93.Jian-Ying Chuang, Wei-Lun Lo, C-Y Ko, S-Y Chou, R-M Chen, K-Y Chang, Jan-Jong Hung, Wu-Chou Su, Wen-Chang Chang, Tsung-I Hsu. Upregulation of CYP17A1 by Sp1-mediated DNA demethylation confers temozolomide resistance through DHEA-mediated protection in glioma. Oncogenesis 2017 May; 6(5): e339.
94.Chia-Sing Lu, Gia-Shing Shieh, Chung-Teng Wang, Bing-Hua Su, Yu-Chu Su, Yi-Cheng Chen, Wu-Chou Su, Pensee Wu, Wen-Horng Yang, Ai-Li Shiau, Chao-Liang Wu. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer. Oncotarget 2017 May; 8(19): 30844-30858.
95.Hong-Tai Tzeng, Chung-Han Tsai, Yi-Ting Yen, Hung-Chi Cheng, Yi-Chieh Chen, Shih-Wen Pu, Yu-Shiuan Wang, Yan-Shen Shan, Yau-Lin Tseng, Wu-Chou Su, Wu-Wei Lai, Li-Wha Wu*, Yi-Ching Wang*. Dysregulation of Rab37-mediated cross-talk between cancer cells and endothelial cells via Thrombospondin-1 promotes tumor neovasculature and metastasis. Clinical Cancer Research 2017 May; 23(9): 2335-2345.
96.James Chih-Hsin Yang, Myung-Ju Ahn, Dong-Wan Kim, Suresh S. Ramalingam, Lecia V. Sequist, Wu-Chou Su, Sang-We Kim, Joo-Hang Kim, David Planchard, Enriqueta Felip, Fiona Blackhall, Daniel Haggstrom, Kiyotaka Yoh, Silvia Novello, Kathryn Gold, Tomonori Hirashima, Chia-Chi Lin, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Pasi A. Janne. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. Journal of Clinical Oncology 2017 Apr; 35(12): 1288-1296.
97.Chung-Ying Lin, Szu-Chun Yang, Wu-Wei Lai, Wu-Chou Su, Jung-Der Wang. Rasch models suggested the satisfactory psychometric properties of the World Health Organization Quality of Life-Brief among lung cancer patients. Journal of Health Psychology 2017 Mar; 22(4): 397-408.
98.Robin Kate Kelley, Chris Verslype, Allen L. Cohn, Tsai-Sheng Yang, Wu-Chou Su, Howard Burris, Fadi Braiteh, Nicholas Vogelzang, Alex Spira, Paul Foster, Y Lee, Eric Van Cutsem. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinu-ation study. Annals of Oncology 2017 Mar; 28(3): 528-534.
99.Wei-Lun Huang, Yi-Lin Chen, Szu-Chun Yang, Chung-Liang Ho, Fang Wei, David T. Wong, Wu-Chou Su*, Chien-Chung Lin*. Liquid biopsy genotyping in lung cancer: ready for clinical utility? Oncotarget 2017 Mar; 8(11): 18590-18608.
100. I-Shou Chang, Shih Sheng Jiang, James Chih-Hsin Yang, Wu-Chou Su, Li-Hsin Chien, Chin-Fu Hsiao, Jih-Hsiang Lee, Chih-Yi Chen, Chung-Hsing Chen, Gee-Chen Chang, Zhaoming Wang, Fang-Yi Lo, Kuan-Yu Chen, Wen-Chang Wang, Yuh-Min Chen, Ming-Shyan Huang, Ying-Huang Tsai, Yu-Chun Su, Wan-Shan Hsieh, Wen-Chi Shih, Shwn-Huey Shieh, Tsung-Ying Yang, Qing Lan, Nathaniel Rothman, Chien-Jen Chen, Stephen J Chanock, Pan-Chyr Yang, Chao A Hsiung. Genetic modifiers of progression-free survival in never-smoking lung adenocarcinoma patients treated with first-line TKIs. American Journal of Respiratory and Critical Care Medicine 2017 Mar; 195(5): 663-673.
101. Wei Jie Seow, Keitaro Matsuo, Chao Agnes Hsiung, Kouya Shiraishi, Wu-Chou Su, Qing Lan et al. Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. Human Molecular Genetics 2017 Jan; 26(2): 454-465.